Journal article · 2024 · Open access

Increased risk of cardiovascular events under the treatments with Janus kinase inhibitors versus biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a retrospective longitudinal population-based study using the Japanese health insurance database

Ryoko Sakai, Eiichi Tanaka, Eisuke Inoue, Masayoshi Harigai

RMD Open, 10(2), e003885 · Published 1 June 2024 · DOI 10.1136/rmdopen-2023-003885

Open full textCite this paper

In brief

“Increased risk of cardiovascular events under the treatments with Janus kinase inhibitors versus biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a retrospective longitudinal population-based study using the Japanese health insurance database” is a 2024 journal article by Ryoko Sakai and 3 co-authors, published in RMD Open. OpenAlex counts 18 citations as of 19 November 2026, which puts it in the top 7% of works published in 2024 by citations. It is open access under a CC BY-NC licence: the full text is free to read at RMD Open.

Citations
18
Most cited in
2026 (10)
Field-weighted impact
4.32
References
46
Authors
4

Abstract

OBJECTIVES: To compare the risk of cardiovascular events among Janus kinase inhibitors (JAKIs), biological disease-modifying antirheumatic drugs (bDMARDs) (tumour necrosis factor inhibitors (TNFIs) and non-TNFIs) and methotrexate (MTX) in Japanese patients with rheumatoid arthritis (RA). METHODS: Using Japanese claims data, patients with RA were enrolled in this study if they had at least one ICD-10 code (M05 or M06), were new users of JAKIs, bDMARDs or MTX between July 2013 and July 2020 and being 18 years old or older. The incidence rate (IR), IR ratio and adjusted hazard ratio (aHR (95% CI)) of cardiovascular events including venous thromboembolism, arterial thrombosis, acute myocardial infarction and stroke were calculated. A time-dependent Cox regression model adjusted for patient characteristics at baseline was used to calculate aHR. RESULTS: In 53 448 cases, IRs/1000 patient-years of the overall cardiovascular events were 10.1, 6.8, 5.4, 9.1 and 11.3 under the treatments with JAKIs, bDMARDs, TNFIs, non-TNFIs and MTX, respectively. The adjusted HRs of JAKIs for overall cardiovascular events were 1.7 (1.1 to 2.5) versus TNFIs without MTX and 1.7 (1.1 to 2.7) versus TNFIs with MTX. CONCLUSIONS: Among patients with RA, individuals using JAKIs had a significantly higher risk of overall cardiovascular events than TNFIs users, which was attributed to the difference in the risk between JAKIs and TNFIs versus MTX. These data should be interpreted with caution because of the limitations associated with the claims database.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Sakai, R., Tanaka, E., Inoue, E., & Harigai, M. (2024). Increased risk of cardiovascular events under the treatments with Janus kinase inhibitors versus biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a retrospective longitudinal population-based study using the Japanese health insurance database. RMD Open, 10(2), e003885. https://doi.org/10.1136/rmdopen-2023-003885

MLA 9

Sakai, Ryoko, et al. “Increased risk of cardiovascular events under the treatments with Janus kinase inhibitors versus biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a retrospective longitudinal population-based study using the Japanese health insurance database.” RMD Open, vol. 10, no. 2, 2024, p. e003885. https://doi.org/10.1136/rmdopen-2023-003885.

Chicago

Sakai, Ryoko, Eiichi Tanaka, Eisuke Inoue, and Masayoshi Harigai. 2024. “Increased risk of cardiovascular events under the treatments with Janus kinase inhibitors versus biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a retrospective longitudinal population-based study using the Japanese health insurance database.” RMD Open 10 (2): e003885. https://doi.org/10.1136/rmdopen-2023-003885.

Harvard

Sakai, R. et al. (2024) ‘Increased risk of cardiovascular events under the treatments with Janus kinase inhibitors versus biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a retrospective longitudinal population-based study using the Japanese health insurance database’, RMD Open, 10(2), p. e003885. doi:10.1136/rmdopen-2023-003885.

IEEE

R. Sakai, E. Tanaka, E. Inoue, and M. Harigai, “Increased risk of cardiovascular events under the treatments with Janus kinase inhibitors versus biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a retrospective longitudinal population-based study using the Japanese health insurance database,” RMD Open, vol. 10, no. 2, p. e003885, 2024, doi: 10.1136/rmdopen-2023-003885.

BibTeX

@article{sakai2024increased,
  title     = {{Increased risk of cardiovascular events under the treatments with Janus kinase inhibitors versus biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a retrospective longitudinal population-based study using the Japanese health insurance database}},
  author    = {Sakai, Ryoko and Tanaka, Eiichi and Inoue, Eisuke and Harigai, Masayoshi},
  journal   = {RMD Open},
  year      = {2024},
  volume    = {10},
  number    = {2},
  pages     = {e003885},
  doi       = {10.1136/rmdopen-2023-003885},
  url       = {https://doi.org/10.1136/rmdopen-2023-003885}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202422
202566
20261010

Its field-weighted citation impact is 4.32: it has been cited 4.32 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies

  • rheumatoid arthritis
  • JAK inhibitors
  • biologic DMARDs
  • tumor necrosis factor inhibitors
  • methotrexate
  • cardiovascular events
  • venous thromboembolism
  • arterial thrombosis

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Sakai, R., Tanaka, E., Inoue, E., & Harigai, M. (2024). Increased risk of cardiovascular events under the treatments with Janus kinase inhibitors versus biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a retrospective longitudinal population-based study using the Japanese health insurance database. RMD Open, 10(2), e003885. https://doi.org/10.1136/rmdopen-2023-003885

How many times has this paper been cited?

18 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at RMD Open: sign in and open the full text from this page.

Who wrote this paper?

Ryoko Sakai, Eiichi Tanaka, Eisuke Inoue, Masayoshi Harigai.

What is the DOI of this paper?

10.1136/rmdopen-2023-003885, permanently at https://doi.org/10.1136/rmdopen-2023-003885. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.